Why We Still Aren't Ready for the Next Ebola

More than a decade after the 2014 Ebola outbreak killed over 11,000 people in West Africa, the international community has learned important lessons about disease response. Yet a closer look at what's actually changed reveals a harder truth: much has improved on paper, but serious gaps remain.

The question experts are asking now is straightforward: have countries and global organizations actually built the systems to prevent another catastrophe, or are they just hoping the next outbreak waits long enough for them to prepare?

What Went Wrong in 2014

The 2014 Ebola outbreak was not inevitable. It became catastrophic because of three specific failures working together.

First, countries lacked the basic ability to detect cases early. Testing labs were too few and too slow. Second, health systems in Guinea, Liberia, and Sierra Leone didn't have the staff or training to isolate patients and stop spread. Third, there was no effective mechanism for neighboring countries to coordinate their response.

A peer-reviewed analysis points out that these were not just problems of not having enough money. The systems themselves were broken. This distinction matters enormously. Giving more money to a broken system doesn't fix it — it just creates expensive failure.

Taking Stock in 2024

In mid-2024, the West African Health Organization and the World Health Organization held a workshop to check on progress. They wanted to know whether the promises made after 2016 had actually turned into real capability.

The timing was deliberate. The COVID-19 pandemic had reminded the world how vulnerable we are to new diseases. This workshop was a chance to see if the system could handle the next major outbreak before it arrives — not during it.

What they found tells a familiar story. International institutions have been through this cycle before. After SARS in 2003, health rules were updated in 2005. When H1N1 arrived in 2009, those rules proved insufficient. Then came Ebola in 2014, which broke them again. Each time, the world learns something genuine. Each time, gaps still slip through.

Whether this time is different remains to be seen.

The Vaccine Is Real, But Not Ready

One genuine success: Merck developed an Ebola vaccine called Ervebo in response to the 2014 crisis. This was a major scientific achievement.

But the vaccine's existence doesn't solve the readiness problem. It's difficult and expensive to manufacture. It requires freezing at ultra-cold temperatures — colder than a normal freezer can go. These constraints matter enormously in poor countries with limited electricity and infrastructure — exactly where an outbreak is most likely to start.

The Global Health Technologies Coalition has documented that when it comes time to actually use the vaccine, manufacturing and storage problems can leave countries without doses when they need them most. It's like having a fire extinguisher that only works in a climate-controlled building.

The National Academies, a prestigious U.S. research organization, reviewed the entire vaccine development pipeline and issued 48 recommendations across seven different areas. The sheer number of recommendations signals how far we still are from having a vaccine that's truly ready to deploy.

America's Own Vulnerabilities

The gaps aren't limited to the countries where Ebola first appeared. The U.S. government itself has preparedness problems.

A congressional watchdog report from 2022 found that the U.S. Department of Health and Human Services hadn't hired or trained enough people to handle remaining vaccine development work. There was no clear schedule for finishing the job.

This reflects a broader pattern: when there's a crisis, governments and institutions invest heavily in health security. When the crisis fades and the threat feels distant, funding and attention drop sharply. The national security community calls this the "readiness treadmill" — you have to run just to stay in place.

The practical implication is concerning. The United States is the world's largest funder of global health security. If the U.S. itself has internal vulnerabilities, that compounds the problems it's trying to help other countries solve.

Time Is the Enemy

Ebola teaches a brutal lesson about speed. Reporting from the Associated Press has reinforced what happened in 2014: the difference between containing an outbreak and watching it spread across multiple countries is often just days, not weeks.

This is the core argument for investing in detection and response systems during the quiet years between outbreaks — when no one is paying attention and no one wants to spend money. If you wait until an outbreak appears, you've already lost the critical window.

A New Global Deal With Missing Pieces

In May 2025, the World Health Organization's member countries adopted a historic pandemic accord — a formal agreement that took more than three years to negotiate.

The accord creates new rules about how countries should prepare, share information about new diseases, and watch for outbreaks. But as Reuters reported at the time, two crucial pieces are still incomplete: money to make it work, and a plan to make sure poor and middle-income countries can actually get vaccines and treatments when they need them.

The equity problem isn't just about fairness. It's operationally essential. If people in the outbreak zone can't access vaccines because they're expensive or scarce, the virus doesn't stay contained to that zone. The 2014 Ebola crisis proved this in real time, at terrible human cost.

The accord is real progress. Whether it actually solves the vaccine access problem depends on details still being negotiated in 2026 — a gap that matters.

Where the System Still Breaks

Looking at all the evidence together — the regional health assessments, the vaccine review, the U.S. government warnings, and the pandemic accord negotiations — a consistent pattern emerges.

Detection systems in West Africa have gotten better but remain fragile. Vaccines exist but are trapped by manufacturing and storage problems. The U.S. pipeline for developing next-generation tools has workforce shortages. The new global agreement has good intentions but incomplete financing and equity mechanisms.

None of this means the last decade was wasted. Integrated disease surveillance systems across the region have been strengthened. The Africa CDC, created in 2017 directly because of Ebola, has proven itself a credible institution — its role during COVID-19 showed it wasn't just a symbolic creation. The 2018–2020 Ebola outbreak in the Democratic Republic of Congo showed that targeted vaccination campaigns can work even in difficult conditions.

The architecture is better than it was. It is not yet reliable. The difference between those two states is what all the recent assessments, recommendations, and negotiations are trying to close.

What Happens Now

The immediate question for health officials and policymakers in 2026 is straightforward: will the pandemic accord actually unlock the money and vaccine access mechanisms before the next major outbreak hits? History suggests cautious optimism mixed with caution. International health agreements have repeatedly shown they can create frameworks. They have repeatedly struggled to convert those frameworks into guaranteed funding that actually flows when needed.

When the West African Health Organization publishes the findings from its 2024 workshop, it will provide the clearest public picture yet of how prepared the region actually is. For anyone responsible for health planning — whether in national governments, international organizations, or vaccine development — that assessment becomes the ground-truth against which to test their plans.

Speed will determine outcomes. The system is better. The vulnerabilities are known. The opportunity to fix them is now — as it always is.